Aprotinin: can its benefits be offset by harmful effects?

This publication has 27 references indexed in Scilit:

• Use of Aprotinin Therapy in a Patient with Factor V Leiden
  Anesthesia & Analgesia, 1997
• Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis
  New England Journal of Medicine, 1996
• Aprotinin Prolongs Whole Blood Activated Partial Thromboplastin Time but Not Whole Blood Prothrombin Time in Patients Undergoing Cardiac Surgery
  Anesthesia & Analgesia, 1995
• Mutation in blood coagulation factor V associated with resistance to activated protein C
  Nature, 1994
• Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purification
  Thrombosis Research, 1990
• Aprotinin (Trasylol) is a competitive inhibitor of activated protein C
  Thrombosis Research, 1989
• Effects of Aprotinin on Hemostatic Mechanisms during Cardiopulmonary Bypass
  The Annals of Thoracic Surgery, 1987
• EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY
  The Lancet, 1987
• ISOLATION FROM BEEF PANCREAS OF CRYSTALLINE TRYPSINOGEN, TRYPSIN, A TRYPSIN INHIBITOR, AND AN INHIBITOR-TRYPSIN COMPOUND
  The Journal of general physiology, 1936
• Über die Inaktivierung des Kallikreins. (VI. Mitteilung über dieses Kreislaufhormon.)
  Hoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1930